HAMBURG, Germany and OXFORD, England, February 9 /PRNewswire-FirstCall/ -- Evotec AG today announced that the Company will give a corporate presentation at the upcoming BIO CEO & Investor Conference, which will take place from 12 to 14 February 2007 at The Waldorf=Astoria Hotel in New York. The presentation will take place on Wednesday, 14 February 2007 at 10.30 pm EST (04.30 pm CET) in the Jade Room of the hotel. It will be webcast live and will be accessible through the Evotec website at www.evotec.com - Investors. A replay will also be available via the website.
In addition, Evotec was invited to participate in the panel discussion, "Dreaming of New Sleep Disorder Drugs", which will take place at 09.00 am EST on Wednesday, 14 February 2007 in the Basildon Room of the hotel.
Evotec has a promising drug candidate (EVT 201) for the treatment of insomnia in Phase II clinical trials. Results of two US studies in primary insomniacs and elderly primary insomniac patients, respectively, are expected for the second half of 2007. EVT 201 is a partial positive allosteric modulator (pPAM) of the GABA A receptor complex. Its partial agonist activity gives EVT 201 a differentiated pre-clinical profile and mechanism of action compared to many currently marketed sleep-promoting agents. In 2005 and 2006, two Phase I/II proof-of-principle studies in subjects with induced insomnia were completed with encouraging results. EVT 201 significantly reduced wake after sleep onset while significantly increasing the total sleep time and quality of sleep with no subjective residual effects.
Dr John Kemp, Chief Research & Development Officer of Evotec, will represent the Company at this panel.
Contact: Evotec AG Anne Hennecke SVP, Investor Relations & Corporate Communications Phone: +49(0)40-56081-286 Fax: +49(0)40-56081-333 E-Mail: anne.hennecke@evotec.com
Evotec AGCONTACT: Contact: Evotec AG, Anne Hennecke, SVP, Investor Relations &Corporate Communications, Phone: +49(0)40-56081-286, Fax:+49(0)40-56081-333, E-Mail: anne.hennecke@evotec.com
